We are excited to once again have assembled many of the leading clinicians and scientists from around the world for the 5th Advances Against Aspergillosis conference. The previous four international meetings were overwhelmingly successful, including the first Advances Against Aspergillosis meeting in 2004 (San Francisco) where we had 364 attendees from 28 countries, the second meeting in 2006 (Athens) with 464 attendees from 44 countries, the third meeting in 2008 (Miami) with 351 attendees from 48 countries, and the fourth meeting in 2010 (Rome) with 533 attendees from 49 countries. The meetings were very productive for exchanging clinical and research ideas and forging new collaborations. This conference has now clearly established itself as the premier forum for detailed and dedicated discussion of all aspects of Aspergillus infection and research, and previously published proceedings from the four prior conferences have been very well-received.
The Aspergillus field is in a state of rapid advancement, including the publication of numerous post-genomic papers and substantial advances in translational and diagnostic research. Additionally, the launch of several newer antifungals in the last few years and anticipated clinical trials of others is an important therapeutic step forward. Antifungal resistance has emerged, newer molecular diagnostic tools are available, and combination therapy is now in clinical trials. Despite the incidence of invasive aspergillosis increasing and disease being the leading fungal cause of patient mortality, prior to the 1st Advances Against Aspergillosis meeting there had been limited communication among experts in the area. This is another chance to gather the world's aspergillosis experts in one venue. A fundamental tenet of this research colloquium continues to be to engender collaborative relationships amongst clinicians, scientists, and industry to further advance the field.
CPD/CME will be applied for through the UK Royal College of Physicians.